The crash of ENMD has simply been stunning since ASCO 2007. From Wall Street's point of view, there is literally NO FAITH whatsoever left in the prospects of this company. On the other hand, the company continues to plod along through numerous phase one and phase two trials, doing what a little biotech is supposed to do, meeting milestone after milestone.I have my sensors up and I have heard no bad news on the science front, which is why the stock plummet is baffling. I thought we would have held at the 1.40 level and traded in that range until December. To say that the company is oversold at this juncture is an understatement. If we dip below a dollar I'll make another significant purchase going long.